Literature DB >> 6802003

Pharmacology of hallucinations induced by long-term drug therapy.

C G Goetz, C M Tanner, H L Klawans.   

Abstract

The authors studied 20 patients with Parkinson's disease and prominent hallucinations related to dopaminergic or anticholinergic therapy. The character of the hallucinations appeared distinct from the classic description of either acute anticholinergic or acute aminergic hallucinatory states. Manipulation of either kind of drug could precipitate or relieve hallucinations in a given patient, which suggests that the dopaminergic/cholinergic systems are reciprocally active in the pathophysiology of long-term drug-induced hallucinatory states in this population.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6802003     DOI: 10.1176/ajp.139.4.494

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  26 in total

Review 1.  Drug-induced cognitive impairment in the elderly.

Authors:  A R Moore; S T O'Keeffe
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

Review 2.  Neuropsychiatry of the basal ganglia.

Authors:  H A Ring; J Serra-Mestres
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-01       Impact factor: 10.154

Review 3.  An update expert opinion on management and research strategies in Parkinson's disease psychosis.

Authors:  Jennifer G Goldman; Christina L Vaughan; Christopher G Goetz
Journal:  Expert Opin Pharmacother       Date:  2011-06-02       Impact factor: 3.889

4.  Hallucinosis in idiopathic Parkinson's disease.

Authors:  J M Graham; R A Grünewald; H J Sagar
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

Review 5.  Psychotic symptoms in Parkinson's disease. From description to etiology.

Authors:  Spiridon Papapetropoulos; D C Mash
Journal:  J Neurol       Date:  2005-07       Impact factor: 4.849

6.  Relationship between age and subtypes of psychotic symptoms in Parkinson's disease.

Authors:  Günes Kiziltan; Sibel Ozekmekçi; Sibel Ertan; Turan Ertan; Ethem Erginöz
Journal:  J Neurol       Date:  2007-03-31       Impact factor: 4.849

7.  The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease.

Authors:  James M Shine; Glenda M Halliday; Moran Gilat; Elie Matar; Samuel J Bolitho; Maria Carlos; Sharon L Naismith; Simon J G Lewis
Journal:  Hum Brain Mapp       Date:  2013-06-13       Impact factor: 5.038

8.  Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease.

Authors:  A Moser; F Siebecker; P Vieregge; P Jaskowski; D Kömpf
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

9.  Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine.

Authors:  E Scholz; J Dichgans
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1985

Review 10.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.